NCT02598934View on ClinicalTrials.gov

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

PHASE4CompletedINTERVENTIONAL
Enrollment

308

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Post Menopausal Osteoporosis
Interventions
DRUG

Ibandronate

Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.

Trial Locations (53)

10016

New York

10461

The Bronx

18901

Doylestown

19047

Langhorne

19131

Philadelphia

19805

Wilmington

21136

Reistertown

21209

Baltimore

21740

Hagerstown

23226

Richmond

27612

Raleigh

28557

Morehead City

28655

Morganton

29307

Spartanburg

29464

Mt. Pleasant

30165

Rome

30309

Atlanta

32720

DeLand

33176

Miami

33186

Miami

33409

West Palm Beach

33461

Palm Springs

34684

Palm Habor

36111

Montgomery

37130

Murfreesboro

37203

Nashville

37813

Morristown

38654

Olive Branch

46202

Indianapolis

50702

Waterloo

53705

Madison

60053

Morton Grove

63108

St Louis

65109

Jefferson City

68131

Omaha

71603

Pine Bluff

71913

Hot Springs

73112

Oklahoma City

75503

Texarkana

76101

Fort Worth

78229

San Antonio

79106

Amarillo

85225

Chandler

85381

Peoria

90211

Beverly Hills

92801

Anaheim

95608

Carmichael

97504

Medford

98405

Tacoma

07003

Bloomfield

00717-1318

Ponce

00927

San Juan

00935

San Juan

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02598934 - A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis | Biotech Hunter | Biotech Hunter